HIV and AIDS Trial, Recruiting NCT00039689 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT00039689
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have HIV-1.
  • People who have suitable veins for research blood draws.
  • People who have a confirmed positive HIV test result meeting current CDC standards, or — for those with a suspected very early HIV infection — a viral load above 2,000 copies/ml with a negative antibody test result.
  • People who are willing and able to attend at least one follow-up visit within the next 4 months, before starting HIV treatment.
  • People whose blood pressure is below 180/100 and whose pulse rate is between 50 and 100 beats per minute (or whose lower pulse rate is considered normal for them).
  • People whose blood counts meet minimum levels: haemoglobin at least 9.0 g/dL, haematocrit at least 28%, and platelets at least 50,000.
  • People who are willing and able to give informed consent, including consent for blood sample storage and genetic testing.
  • People who have never taken antiretroviral (HIV) treatment, have not taken it in the last six months, or were previously enrolled in a related study with samples already stored.
  • People who acquired HIV while taking medication to prevent HIV infection (pre-exposure prophylaxis) may also be eligible, provided their HIV diagnosis meets the required criteria.
  • People enrolled in a related study in the past three months who complete a specific blood collection procedure within 4 weeks of starting HIV treatment may also be eligible.
  • People with very limited recent HIV treatment use (no more than 4 weeks before the screening visit) may be eligible if the trial investigators determine that this use would not affect the scientific value of the study (confirm with trial site).

Who may not be able to join:

  • People who are pregnant or breastfeeding.
  • People who are currently misusing alcohol or other substances in a way that could affect their safety or ability to follow the study requirements.
  • People who have a medical or other condition that, in the investigators' judgement, would make participation unsuitable (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Susan L Moir, Ph.D., National Institute of Allergy and Infectious Diseases (NIAID)

Phone: (301) 435-8003

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
12 July 2002

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To further investigate differences in the immunologic function of various lymphocyte subsets in PWH who are treated early after transmission of HIV and during the chronic phase of the disease.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov